Table 3 For patients with the largest brain metastasis over 1 cm: univariate and multivariate Cox regression analyses of covariables associated with survival after the diagnosis of brain metastasis.

	Univariate analyses		Multivariate analyses
	HR (95%CI)	P-value	HR (95%CI)	P-value
Age
>65 vs. ≦65	1.32 (0.77 to 2.29)	0.318
Female vs. male	0.59 (0.35 to 1)	0.052
Initial Clinical stage
III–IV vs. I–II	1.38 (0.5 to 3.81)	0.538
Initial Tumor classification
III–IV vs. I–II	0.92 (0.5 to 1.67)	0.772
Initial Nodal classification
2–3 vs. 0–1	1.67 (0.98 to 2.83)	0.058	2.23 (1.27 to 3.92)	0.005
EGFR mutation
Exon 19 or 21
Yes vs. no	0.815 (0.43 to 1.55)	0.533
Exon 19
Yes vs. no	0.68 (0.41 to 1.15)	0.15
Exon 20
Yes vs. no	0.82 (0.372 to 1.81)	0.622
Exon 21
Yes vs. no	1.12 (0.65 to 1.9)	0.687
Brain surgery
Yes vs. no	0.5 (0.3 to 0.84)	0.008	0.49 (0.29 to 0.83)	0.008
RT boost dose >3750cGy
Yes vs. no	1.1 (0.65 to 1.85)	0.726
Number of lines of systemic chemotherapy
>3 vs. 0–3	1.18 (0.53 to 2.61)	0.684
TKI name
afatinib
Yes vs. no	1.16 (0.46 to 2.9)	0.757
erlotinib
Yes vs. no	0.57 (0.34 to 0.95)	0.031	0.49 (0.29 to 0.85)	0.011
gefitinib
Yes vs. no	1.43 (0.83 to 2.48)	0.199
osimertinib
Yes vs. no	1.31 (0.41 to 4.19)	0.655
Number of lines of TKI
>1 vs. 1	0.692 (0.4 to 1.2)	0.192
ECOG performance status
1 vs. 0	0.96 (0.57 to 1.62)	0.889
2 vs. 0	0.59 (0.14 to 2.47)	0.467
Smoking status
Former or current vs. never	1.25 (0.71 to 2.2)	0.434
Symptomatic brain metastases
Yes vs. no	0.73 (0.31 to 1.71)	0.471
No. of brain metastases
2–3 vs. 1	1.62 (0.75 to 3.49)	0.216
>3 vs. 1	1.4 (0.58 to 3.39)	0.451
dsGPA
0.5–1.5 vs. 2–4	1.38 (0.74 to 2.55)	0.311

Abbreviations: EGFR: epidermal growth factor receptor; RT: radiation therapy; TKI: tyrosine kinase inhibitor; ECOG: Eastern Cooperative Oncology Group; dsGPA: disease-specific Graded Prognostic Assessment.

Search